Evidence map›Paper›PMID 37561978›Full record

ArticleJCO global oncology2023

Redefining Cancer Research Priorities in Low- and Middle-Income Countries in the Post-COVID-19 Global Context: A Modified Delphi Consensus Process.

Louis Fox, Aida Santaolalla, Jasmine Handford, Richard Sullivan, Julie Torode, Verna Vanderpuye, C S Pramesh, Layth Mula-Hussain, Shaymaa AlWaheidi, Lydia E Makaroff and 4 more

Open access · goldAbstract readConsensus Statement
In one paragraph

Article in JCO global oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.7field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 5 countries.

Louis FoxTranslational Oncology and Urology Research (TOUR), Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.ORCID 0000-0002-8280-1797
Aida SantaolallaTranslational Oncology and Urology Research (TOUR), Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.
Jasmine HandfordTranslational Oncology and Urology Research (TOUR), Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.ORCID 0000-0002-5341-0949
Richard SullivanGlobal Oncology Group, Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.ORCID 0000-0002-6435-1825
Julie TorodeGlobal Oncology Group, Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.ORCID 0000-0002-9755-3968
Verna VanderpuyeNational Centre for Radiotherapy, Oncology and Nuclear Medicine, Korle Bu Teaching Hospital, Accra, Ghana.ORCID 0000-0003-3656-6965
C S PrameshTata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-3635-0083
Layth Mula-HussainSultan Qaboos Comprehensive Cancer Care and Research Centre, Muscat, Oman.ORCID 0000-0003-0218-7270
Shaymaa AlWaheidiGlobal Oncology Group, Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.ORCID 0000-0002-1485-7078
Lydia E MakaroffWorld Bladder Cancer Patient Coalition, Brussels, Belgium.ORCID 0000-0001-7381-5743
Ranjit KaurAdvanced Breast Cancer Global Alliance, Petaling Jaya, Malaysia.
Clara MackayWorld Ovarian Cancer Coalition, Toronto, ON, Canada.
Deborah MukherjiNaef K Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon.ORCID 0000-0002-0192-5828
Mieke Van HemelrijckTranslational Oncology and Urology Research (TOUR), Centre for Cancer, Society and Public Health, King's College London, London, United Kingdom.ORCID 0000-0002-7317-0858
King's College London · GBAmerican University of Beirut Medical Center · LBHomi Bhabha National Institute · INKorle Bu Teaching Hospital · GHOvarian Cancer Canada · CAWorld Bladder Cancer Patient Coalition aisbl

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe post-COVID-19 funding landscape for cancer research globally has become increasingly challenging, particularly in resource-challenged regions (RCRs) lacking strong research ecosystems. We aimed to produce a list of priority areas for cancer research in countries with limited resources, informed by researchers and patients.

methodsCancer experts in lower-resource health care systems (as defined by the World Bank as low- and middle-income countries; N = 151) were contacted to participate in a modified consensus-seeking Delphi survey, comprising two rounds. In round 1, participants (n = 69) rated predetermined areas of potential research priority (ARPs) for importance and suggested missing ARPs. In round 2, the same participants (n = 49) rated an integrated list of predetermined and suggested ARPs from round 1, then undertook a forced choice priority ranking exercise. Composite voting scores (

resultsThe top ARP was research into strategies adapting guidelines or treatment strategies in line with available resources (particularly systemic therapy) (

conclusionAreas of strategic priority favored by cancer researchers in RCRs are related to adaptive treatment guidelines; sustainable implementation of cancer registries; prevention strategies; value-based and affordable cancer care; investments in research capacity building; epidemiologic work on local risk factors for cancer; and combatting inequities of prevention and care access.

Indexed as

COVID-19NeoplasmsDelphi TechniqueDeveloping CountriesEcosystemHumansResearch

Identifiers

PMID37561978
PMCPMC10857688
OpenAlexW4385727502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.